STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate.

Measuring the lymphocytes—white blood cells that fight infection—in a patient's blood can be used to predict outcomes in ...

Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute ...

High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...